Strategies to optimize the brain availability of central nervous system drug candidates
- 18 March 2011
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 6 (4), 371-381
- https://doi.org/10.1517/17460441.2011.564158
Abstract
Access to the CNS is essential for most neurotherapeutics to elicit their effects. Leveraging design strategies incorporating physicochemical properties, in vitro and in vivo assays to predict and measure brain penetration, and brain delivery approaches may enable the drug discovery community to improve access of drug candidates into the CNS compartment. This article reviews aspects of the most recent molecular design, in vitro and in vivo strategies, and delivery technologies to optimize the unbound brain concentrations (C (b,u)) of CNS molecules. Through this, the article provides insight into recent ideas and concepts in CNS drug molecule design, methods for evaluating CNS drug exposures and alternative approaches to maximize drug access to neurocompartments. The most pharmacologically relevant measure in assessing a compound's pharmacodynamic response in the CNS is its C (b,u). The utilization of emerging design strategies, together with in vitro and in vivo assays, may enable the design of molecules with optimal C (b,u):C (p,u) (C (p,u), unbound plasma concentration) and appropriate C (b,u,) to elicit a biological response from the neurotherapeutic target. Where drug properties intrinsically render a compound CNS impaired, using novel CNS delivery approaches may result in sufficient C (b,u) to furnish a biological response.Keywords
This publication has 73 references indexed in Scilit:
- Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-Species Pharmacologic Exposure–Response RelationshipsPublished by Elsevier BV ,2010
- Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in RatsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2009
- Receptor Occupancy and Brain Free FractionDrug Metabolism and Disposition, 2009
- Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial FluidDrug Metabolism and Disposition, 2008
- On The Rate and Extent of Drug Delivery to the BrainPharmaceutical Research, 2007
- Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,uand Correlation of in Vitro, Preclinical, and Clinical DataJournal of Pharmacology and Experimental Therapeutics, 2007
- Drug development for CNS disorders: strategies for balancing risk and reducing attritionNature Reviews Drug Discovery, 2007
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discoveryBiopharmaceutics & Drug Disposition, 2002
- Computational approaches to the prediction of the blood–brain distributionAdvanced Drug Delivery Reviews, 2002